Mutant Myocilin Disease Model Patent Granted
Summary
The USPTO has granted Regeneron Pharmaceuticals, Inc. a patent (US12582104B2) for a mutant myocilin disease model. This patent covers non-human animal models engineered to express human myocilin, intended for assessing therapeutic reagents for glaucoma.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582104B2 to Regeneron Pharmaceuticals, Inc. The patent covers novel non-human animal models, their genomes, and cells that comprise a humanized MYOC locus. These models are designed to express human or chimeric myocilin proteins and are intended for use in evaluating the efficacy of reagents targeting human myocilin, specifically for the treatment of glaucoma.
This patent grant is primarily of interest to pharmaceutical and biotechnology companies involved in glaucoma research and development. While it does not impose direct compliance obligations on regulated entities, it signifies intellectual property protection for specific research tools. Companies working on similar therapeutic approaches should be aware of this granted patent to navigate potential intellectual property landscapes and avoid infringement.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Mutant myocilin disease model and uses thereof
Grant US12582104B2 Kind: B2 Mar 24, 2026
Assignee
Regeneron Pharmaceuticals, Inc.
Inventors
Gaurang Patel, Charleen Hunt, Yajun Tang, Qing Fang, Guochun Gong, Ying Hu, Carmelo Romano
Abstract
Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized MYOC locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized MYOC locus express a human myocilin protein or a chimeric myocilin protein, fragments of which are from human myocilin. Methods are provided for using such non-human animals comprising a humanized MYOC locus to assess in vivo efficacy of human-myocilin-targeting reagents and reagents for treating glaucoma.
CPC Classifications
A01K 67/0275 C07K 14/005 C07K 14/47 C12N 9/22 C12N 15/113 C12N 15/86
Filing Date
2022-12-08
Application No.
18717225
Claims
27
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.